Stifel Nicolaus Cuts American Well (NYSE:AMWL) Price Target to $6.00

American Well (NYSE:AMWL) had its target price trimmed by Stifel Nicolaus from $8.00 to $6.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a hold rating on the stock.

A number of other equities analysts also recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of American Well in a report on Wednesday, October 8th. Wells Fargo & Company cut their price target on shares of American Well from $15.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, August 7th. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.33.

American Well Stock Up 2.8%

Shares of AMWL opened at $4.21 on Wednesday. American Well has a fifty-two week low of $4.05 and a fifty-two week high of $12.95. The company’s fifty day moving average is $5.99 and its two-hundred day moving average is $6.96. The firm has a market cap of $67.91 million, a PE ratio of -0.58 and a beta of 1.24.

American Well (NYSE:AMWL) last issued its earnings results on Tuesday, November 4th. The company reported ($1.74) earnings per share for the quarter, topping the consensus estimate of ($1.83) by $0.09. American Well had a negative return on equity of 39.80% and a negative net margin of 42.80%.The business had revenue of $56.29 million for the quarter, compared to analyst estimates of $54.56 million. American Well has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts anticipate that American Well will post -9.34 earnings per share for the current year.

Insider Activity at American Well

In other American Well news, insider Phyllis Gotlib sold 4,959 shares of the stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $6.11, for a total value of $30,299.49. Following the completion of the sale, the insider owned 127,151 shares of the company’s stock, valued at $776,892.61. This trade represents a 3.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Deborah C. Jackson sold 4,531 shares of American Well stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $6.56, for a total transaction of $29,723.36. Following the sale, the director owned 39,132 shares in the company, valued at $256,705.92. This represents a 10.38% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 49,383 shares of company stock worth $331,514. 11.82% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On American Well

Large investors have recently added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new stake in American Well during the 2nd quarter worth $39,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of American Well during the third quarter valued at about $62,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of American Well during the second quarter valued at about $89,000. Engineers Gate Manager LP purchased a new stake in shares of American Well during the second quarter worth about $101,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of American Well by 16.5% in the second quarter. JPMorgan Chase & Co. now owns 14,720 shares of the company’s stock worth $131,000 after acquiring an additional 2,081 shares in the last quarter. 56.05% of the stock is owned by institutional investors and hedge funds.

American Well Company Profile

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members.